-
EU approves bispecific antibody Tecvayli (teclistamab) for the treatment of adults with relapsed/refractory multiple myeloma (RRMM)
Time of Update: 2022-09-24
Janssen announced today that the European Commission (EC) has approved the conditional marketing of Tecvayli (teclistamab), a bispecific antibody targeting B cell maturation antigen (BCMA), for the treatment of adults with relapsed/refractory multiple myeloma (RRMM).
-
FDA approves ibrutinib for children with chronic GVHD
Time of Update: 2022-09-24
ly/3cgRdJ8 Based on the results of the Phase 1/2 iMAGINE trial, the FDA has approved ibrutinib for patients with chronic graft-versus-host disease in children .
ly/3cgRdJ8 Based on the results of the Phase 1/2 iMAGINE trial, the FDA has approved ibrutinib for patients with chronic graft-versus-host disease in children .
-
Researchers have discovered a rare inherited blood disease HLH new pathogenic gene
Time of Update: 2022-09-22
A hypothetical model of NBAS gene defects causing HLH to occurSource: Beijing Institute of Genomics, Chinese Academy of SciencesHemophagocytic syndrome (HLH) is a severely life-threatening rare blood disease with an incidence of only one in a million, named after the phenomenon of phagocytes commonly found in the bone marrow of patients.
-
Focusing on the difficulties and based on practice, Professor Sun Jing and Feng Xiaoqin broke the forbidden area of hemophilia heart surgery and played the voice of China
Time of Update: 2022-09-21
Professor Feng XiaoqinThe patient is a child with congenital heart disease, the ventricular septal defect has a large flow of components, and has formed severe pulmonary hypertension, mitral valve moderate to severe insufficiency, severe condition resulting in cardiac abnormalities nearly 2 times larger than the same age, and combined with severe hemophilia A, accompanied by high titer FVIII inhibitors.
-
From the experience of the star center NKTCL, we talked about the development prospects of immune checkpoint inhibitors
Time of Update: 2022-09-21
*Modified SMILE protocol: methotrexate, calcium folinate, ifosfamide, mesna, dexamethasone, etoposide, levoastase; P-Gemox: Peppases, gemcitabine, oxaliplatinUnlimited vitality: PD-1 antibody in the field of NKTCL Exploration Professor Zhu Zunmin of Henan Provincial People's Hospital first introduced the pathogenesis of NKTCL and the current first-line treatment plan, and based on the application experience of the center, said that the P-GemoxD protocol in early NKTCL patients is better than the CHOP-like protocol.
-
Qunyinghui No. 10 Intensive Literature Reading: A New Direction of Targeted Therapy for B-Cell Lymphoma
Time of Update: 2022-09-21
Professor Wang Li pointed out that compared with traditional chemotherapy, ADC drugs can bring more accurate targeted therapy, and previous studies carried out by the department have shown that Pola+BR still has a good efficacy for patients who have previously received CAR-T treatment failure or are resistant to chemotherapy, and the prospect is promising.
-
First-line treatment options for elderly patients with acute myeloid leukemia from an international perspective: intensive chemotherapy versus non-intensive therapy
Time of Update: 2022-09-21
Given that the addition of venequera to demethylated drugs or low-dose cytarabine therapy significantly improves response rates and survival, the role of intensive chemotherapy in older patients with AML (aged 60-74 years but without significant clinical comorbidities) who do not meet the criteria for inclusion in VIALE-A or VIALE-C is increasingly questionable, The results showed a median OS of 14.
-
JHO (IF=23) In a multi-unit collaboration with Xiamen University, Xu Bing/Li Zhiming/He Xuhua revealed the evolution of the tumor immune microenvironment in follicular lymphoma patients over a 24-month period
Time of Update: 2022-09-21
Patients with follicular lymphoma have a poor prognosis if they experience disease progression (POD24) within 24 months.
Patients with follicular lymphoma have a poor prognosis if they experience disease progression (POD24) within 24 months.
-
Preliminary clinical results of ESMO field direct-attack anti-CD47 monoclonal antibody Lemzoparlimab combined with azacytidine in the treatment of newly diagnosed patients with HR-MDS
Time of Update: 2022-09-21
Figure 1Among the 29 patients with assessable efficacy ≥ 4 months of initial treatment, the overall response rate (ORR) was 86.
Figure 1Among the 29 patients with assessable efficacy ≥ 4 months of initial treatment, the overall response rate (ORR) was 86.
-
Unprecedented and exciting! The 18th National Conference on Red Blood Cell Disease (Anemia) of the Chinese Medical Association was grandly opened
Time of Update: 2022-09-21
The 18th National Conference on Red Blood Cell Disease (Anemia), sponsored by the Chinese Medical Association and the Hematology Branch of the Chinese Medical Association, undertaken by the Henan Medi
-
ESMO Direct Hit ORR 42.2% and DCR 75.6%! Preliminary results of a Phase I study on the treatment of relapsed refractory B-NHL by TRS005 were published
Time of Update: 2022-09-21
Professor Shi Yuankai's team at the Cancer Hospital of the Chinese Academy of Medical Sciences conducted a Phase I dose escalation and extension study (CTR20182204) to explore the safety, pharmacokinetics and preliminary efficacy of TRS005 in patients with CD20+ relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
-
Professor Sun Zhiqiang: The fire of innovation, casting the blade of treatment, from the real drug use of Rotxip and core research β- the future treatment trend of local poverty
Time of Update: 2022-09-21
For the treatment of β-thalassemia (hereinafter referred to as "β-ground poverty"), the previous means were more limited. Some patients rely on long-term blood transfusions and face multiple dilemmas
-
Ke Xiaoyan and Professor Hu Kai's team: The provider CD7 CAR-T treatment of recurrent T-ALL/LBL after allogeneic hematopoietic stem cell transplantation is safe and has a high remission rate, which is worth looking forward to
Time of Update: 2022-09-21
As the efficacy of CAR-T therapy in B-cell lymphoma is becoming recognized, several studies have focused on patients with refractory/relapsing T-ALL/LBL. It is well known that refractory/relapsing T-A
-
A clinical manifestation of malignant blood disease - pruritus
Time of Update: 2022-09-21
Brett, MDIn a large retrospective study, lymphoma, myeloma, and myeloid leukemia were the most closely associated malignant blood diseases with pruritus.
Brett, MDIn a large retrospective study, lymphoma, myeloma, and myeloid leukemia were the most closely associated malignant blood diseases with pruritus.
-
Professor Huang Huiqiang: Pola sends charcoal in the snow to help patients with non-transplantable R/R DLBCL to rekindle hope
Time of Update: 2022-09-21
GuideThe opening of every unknown world has been bravely foreseen by pioneers; Every journey of stealth in the dark of night, there are lighters fearlessly leading the way. The series of reports on "S
-
Case review Professor Jin Jie: There is no way out of thousands of twists and turns, the peak circuit has turned into a good situation, and the geritinib headwind flips to reconstruct the new vitality of life for AML patients
Time of Update: 2022-09-21
The continuous development of targeted drugs in the treatment of acute myeloid leukemia (AML) has led to the rebirth of more patients with AML. At present, AML treatment has entered a new era, geritin
-
Science Advances: Studies have confirmed that cfDNA contains tumor-specific TF binding information, which can be used to map tumor regulation using plasma
Time of Update: 2022-09-20
Since the length of DNA fragments protected by TF and nucleosomes is significantly different, cfDNA helps to directly map protein-DNA interactions in the cells of its origin, studying the function of TF in the source tissue, but it is not yet possible to routinely map TF binding sites (TFBS) in tumors in the clinic.
-
[When anti-thrombosis meets bleeding] Dual antiplatelet therapy for acute coronary syndrome and prevention and treatment of bleeding complications
Time of Update: 2022-09-20
), and the risk of ischemia (including the location and extent of coronary artery disease); For patients receiving stents, the placement of stents, postoperative time of stents (very high mortality from DISCONTINUation of DAPT within 1 month), and stent type (BMS and next-generation DES) should also be considered to comprehensively evaluate and formulate adjustments for antiplatelet drugs.
-
Blood Cancer J: two-dose versus three-agent induction chemotherapy for pediatric acute myeloid leukemia: a randomized controlled trial
Time of Update: 2022-09-20
Patients aged 1 to 18 years newly diagnosed with AML were randomized to receive two cycles of daunorubicin and ara-C (DA) induction chemotherapy or two cycles of ara-C, daunorubicin, and etoposide (ADE).
-
Blood Cancer J: Is R-CEOP the first choice for patients with anthracycline DLBCL who are not suitable for first-line treatment?
Time of Update: 2022-09-20
： ， 。 Video Applet Like, double tap to cancel Like in Watch, tap twice to cancel Watch R-CHOP is the standard protocol for diffuse large B-cell lymphoma (DLBCL), but as with all anthracyclines, doxorubicin has dose-dependent cardiotoxicity, particularly in patients with congestive heart failure and in patients with previous exposure to anthracyclines.
